

- of theranostic alkylphosphocholine chelates *in vivo* [abstract]. *J Nucl Med.* 2018; 59(suppl):533.
7. Aluicio-Sarduy E, Hernandez R, Olson AP, et al. Production and *in vivo* PET/CT imaging of the theranostic pair ^{132/135}La. *Sci Rep.* 2019;9:10658.
 8. Aluicio-Sarduy E, Thiele NA, Martin KE, et al. Establishing radiolanthanum chemistry for targeted nuclear medicine applications. *Chemistry.* 2020;26:1238–1242.
 9. Bailey T, Lakes A, An D, Gauny S, Abergel R. Biodistribution studies of chelated Ce-134/La-134 as positron-emitting analogues of alpha-emitting therapy radionuclides [abstract]. *J Nucl Med.* 2019;60(suppl):130.
 10. Hernandez R, Walker KL, Grudzinski JJ, et al. ⁹⁰Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell non-Hodgkin's lymphoma. *Commun Biol.* 2019;2:79.
 11. Hernandez R, Grudzinski JJ, Aluicio-Sarduy E, et al. ¹⁷⁷Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer. *J Nucl Med.* 2020;61:1187–1194.
 12. Hernandez R, Aluicio-Sarduy E, Grudzinski J, et al. ²²⁵Ac-NM600 targeted alpha therapy extends survival in a model of triple negative breast cancer [abstract]. *J Med Imaging Radiat Sci.* 2019;50(suppl):S35.
 13. Thiele NA, Brown V, Kelly JM, et al. An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. *Angew Chem Int Ed Engl.* 2017;56:14712–14717.
 14. Li WP, Ma DS, Higginbotham C, et al. Development of an *in vitro* model for assessing the *in vivo* stability of lanthanide chelates. *Nucl Med Biol.* 2001;28:145–154.
 15. Kelly VJ, Wu S-T, Gottumukkala V, et al. Preclinical evaluation of an ¹¹¹In/²²⁵Ac theranostic targeting transformed MUC1 for triple negative breast cancer. *Theranostics.* 2020;10:6946–6958.

Errata

In the article “Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of ¹⁷⁷Lu-DOTA-EB-TATE,” by Liu et al. (*J Nucl Med.* 2021;62:386–392), the affiliation for Orit Jacobson was incorrect. The correct affiliation for Dr. Jacobson should read: “National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.” The authors regret the error.

In the article “The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism” (*J Nucl Med.* 2021;62:304–312), by Mariani et al., the order of two terms was inadvertently reversed in the following sentence: “Antithyroid drugs must be discontinued for at least 2–3 wk in the case of carbimazole and methimazole and at least 3 d in the case of propylthiouracil.” The correct sentence should read: “*Antithyroid drugs must be discontinued for at least 3 d in the case of carbimazole and methimazole and at least 2–3 wk in the case of propylthiouracil.*” The authors regret the error.